Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

被引：2
|
作者：
Tougeron, D. [1 ]
Laurent-Puig, P. [2 ]
Zaanan, A. [2 ,3 ]
机构：
[1] Univ Poitiers Hosp, Dept Gastroenterol, Poitiers, France
[2] INSERM, UMR S775, Paris, France
[3] European Georges Pompidou Univ Hosp, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 12期
关键词：
CIRCULATING MUTANT-DNA; ANTI-EGFR THERAPY; K-RAS MUTATIONS; ACQUIRED-RESISTANCE; CETUXIMAB; PCR;
D O I：
10.1038/bjc.2014.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2379 / 2380
页数：3
相关论文
共 50 条
  • [31] Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
    Goel, Sanjay
    Ocean, Allyson J.
    Parakrama, Ruwan Y.
    Ghalib, Mohammad H.
    Chaudhary, Imran
    Shah, Umang
    Viswanathan, Sengottuvel
    Kharkwal, Himanshu
    Coffey, Matthew
    Maitra, Radhashree
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1148 - 1156
  • [32] Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
    Spindler, Karen-Lise Garm
    Pallisgaard, Niels
    Vogelius, Ivan
    Jakobsen, Anders
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1177 - 1185
  • [33] PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer
    Harvey, Harry
    Chen, Eric Xueyu
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1987 - 1992
  • [34] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04): : 337 - 345
  • [35] Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Serova, Maria
    Riveiro, Maria Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [36] Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan
    Pallisgaard, N.
    Spindler, K. G.
    Vogelius, I. S.
    Jakobsen, A. K. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?
    Selcukbiricik, F.
    Yildiz, O.
    Tural, D.
    Ozturk, M. A.
    Demir, G.
    Ozguroglu, M.
    Erdamar, S.
    Buyukunal, E.
    Mandel, N. M.
    Serdengecti, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S397 - S397
  • [38] Non-engineered T cells with specific anticancer effects in KRAS-mutated colorectal cancer
    Lim, Sunki
    Gho, Yujeong
    Kim, Seoyoung
    Kim, Min Ki
    Park, Jong Seob
    Lee, Wang Jun
    Lee, Young-Kwan
    Moon, Hyoun Jong
    CANCER RESEARCH, 2023, 83 (07)
  • [39] KRAS Status: Predictor in the targeted treatment of metastatic colorectal cancer
    Beddar, L.
    Hamdouche, S.
    Sifi, K.
    Benahsene, K.
    Abadi, N.
    Filali, T.
    VIRCHOWS ARCHIV, 2015, 467 : S161 - S161
  • [40] Avutometinib plus cetuximab after chemotherapy in patients with KRAS-mutated metastatic colorectal cancer: Results of phase 1 dose escalation.
    Gujarathi, Rushabh
    Polite, Blase N.
    Cursio, John
    Desgardin, Aurelie
    El-Naggar, Ryan
    Savaiano, Cindy
    Wherity, Katherine
    Shaik, Afnan
    Nambiar, Chetan
    Arndt, Nicole
    Serbas, Lianna
    Neerukonda, Anu Radha
    Liao, Chih-Yi
    Shergill, Ardaman
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 199 - 199
12345